VARIZIG®

VARIZIG [Varicella Zoster Immune Globulin (Human)] is indicated in the United States for post-exposure prophylaxis of varicella (chickenpox) in high risk patient groups including immunocompromised children, newborns, and pregnant women. VARIZIG is intended to reduce the severity of chickenpox infections in these patients.

VARIZIG is a hyperimmune product that contains antibodies specific for the Varicella zoster virus which causes the viral infection known as chickenpox.

VARIZIG is indicated for, and the Centers for Disease Control (CDC) recommends VARIZIG for postexposure prophylaxis of varicella for persons at high risk for severe disease who lack evidence of immunity to varicella. VARIZIG is approved for administration as soon as possible following varicella-zoster virus exposure, ideally within 96 hours (4 days) for greatest effectiveness. VARIZIG administration is intended to reduce the severity of varicella.

VARIZIG® ‐ Aptevo

Size:
125 IU
NDC #:
53270-0126-02
Download:
PI